Whitehawk Therapeutics (WHWK) Cash from Financing Activities (2010 - 2026)
Whitehawk Therapeutics (WHWK) posted quarterly Cash from Financing Activities of $25000.0 for Q4 2025, down 52.83% year-over-year from $53000.0 in Q4 2024, and up 102.94% quarter-over-quarter from -$850000.0 in Q2 2025.
Powered by 
Analysis
Whitehawk Therapeutics (WHWK) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported Cash from Financing Activities for 12 consecutive years, with $25000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Financing Activities fell 52.83% year-over-year to $25000.0; the TTM figure through Mar 2026 stood at -$825000.0 (down 100.87% YoY), while the FY2025 annual figure was $94.4 million, up 72496.92% from the prior year.
- Cash from Financing Activities improved to $25000.0 in Q4 2025 per WHWK's latest filing, from -$850000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $141.7 million in Q3 2021 and bottomed at -$850000.0 in Q2 2025.
- Historically, Cash from Financing Activities has averaged $17.2 million across 5 years, with a median of $61639.5 in 2021.
- On a YoY basis, Cash from Financing Activities climbed as much as 952110.0% in 2025 and fell as far as 1077.01% in 2025.
- Whitehawk Therapeutics' Cash from Financing Activities stood at $88000.0 in 2021, then tumbled by 221.59% to -$107000.0 in 2022, then surged by 174.77% to $80000.0 in 2023, then slumped by 33.75% to $53000.0 in 2024, then tumbled by 52.83% to $25000.0 in 2025.
- Business Quant data shows WHWK's Cash from Financing Activities at $25000.0 in Q4 2025, -$850000.0 in Q2 2025, and $95.2 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Whitehawk Therapeutics | 377.13 Mn | 377.13 Mn | - | 81.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 81.84 Mn |
| Dec 31, 2025 | 25,000.00 |
| Jun 30, 2025 | -850,000.00 |
| Mar 31, 2025 | 95.20 Mn |
| Dec 31, 2024 | 53,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Dec 31, 2023 | 80,000.00 |
| Sep 30, 2023 | -75,000.00 |
| Jun 30, 2023 | 313,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Dec 31, 2022 | -107,000.00 |
| Sep 30, 2022 | 72.52 Mn |
| Jun 30, 2022 | -87,000.00 |
| Mar 31, 2022 | 298,000.00 |
| Dec 31, 2021 | 88,000.00 |
| Sep 30, 2021 | 141.72 Mn |
| Jun 30, 2021 | -71,279.00 |
| Mar 31, 2021 | 70,279.00 |
| Dec 31, 2018 | 76.00 |